Ishibashi Hiroki, Shimada Mitsuo, Kamisawa Terumi, Fujii Hideki, Hamada Yoshinori, Kubota Masayuki, Urushihara Naoto, Endo Itaru, Nio Masaki, Taguchi Tomoaki, Ando Hisami
Department of Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
J Hepatobiliary Pancreat Sci. 2017 Jan;24(1):1-16. doi: 10.1002/jhbp.415. Epub 2017 Jan 22.
Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.
到目前为止，尚无关于先天性胆管扩张症（CBD）的实用临床指南。在这篇综述文章中，日本先天性胆管扩张症研究小组（JSCBD）提议制定CBD的临床实践指南。由于循证文献相对较少，我们决定以专家共识为基础制定指南，并参考医学文献。负责该指南的编辑委员会成员共考虑了20个临床问题（CQs）。这些CQs涵盖了CBD的不同方面：（1）概念与病理学（3个CQs）；（2）诊断（6个CQs）；（3）胰胆管并发症（3个CQs）；治疗与预后（8个CQs）。CQs的每条陈述和评论均由指南委员会成员做出。CQs经编辑委员会成员和CBD指南评估委员会审核后最终获批。制定这些指南旨在为CBD的临床管理实践提供帮助；其内容侧重于临床实用性，还包括CBD的一般信息，以使这种疾病得到更广泛的认识。
